Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지

Pulmonary Resection Combined with Isoniazid-and Rifampin-based Drug Therapy for Patients with Multidrug-resistant Tuberculosis

다제내성 폐결핵 환자에서 폐절제술 후 일차 항결핵제 치료

  • Park, Seung-Kyu (Department of chest surgery, National Masan Tuberculosis Hospital) ;
  • Kim, Jin-Hee (Department of chest surgery, National Masan Tuberculosis Hospital) ;
  • Kim, Jun-Ho (Department of chest surgery, National Masan Tuberculosis Hospital)
  • 박승규 (국립마산결핵병원 흉부외과) ;
  • 김진희 (국립마산결핵병원 흉부외과) ;
  • 박준호 (국립마산결핵병원 흉부외과)
  • Received : 2005.06.09
  • Accepted : 2005.04.09
  • Published : 2005.08.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background : To evaluate the clinical efficacy of pulmonary resection combined with first-line antituberculous drug therapy in patients with well-localized, cavities-containing pulmonary multidrug-resistant tuberculosis (MDR-TB). Method : From February 1998, seventeen patients with well-localized, cavities-containing pulmonary MDR-TB were enrolled and followed prospectively up to December 2004. After radical pulmonary resection, the patients were treated with antituberculous drugs comprising of isoniazid (H), rifampin (R), pyrazinamide (Z), ethambutol (E), and streptomycin (S) (3HERZS/3HERS/6HER). Results : All recovered isolates of M. tuberculosis were resistant to both isoniazid and rifampin, and to a mean of 4.8 antituberculous drugs (range, 2 to 7 drugs). Surgical procedures included lobectomy (13 patients), lobectomy plus segmentectomy (3 patients), and pneumonectomy (1 patient). The median time for postoperative sputum smear and culture conversion was 2 days (range, 1 to 23 days). Fifteen (94%) patients had durable cures (mean follow-up period, 39.0 months). One patient failed to convert her sputum and was successfully switched to second-line therapy; one patient developed active disease again almost 7 years later, likely due to re-infection with a new M. tuberculosis strain. Conclusion : Radical resection combined with administration of first-line antituberculous agents was effective in patients with well-localized, cavities-containing pulmonary MDR-TB.

배 경 : 다제내성 폐결핵환자에서 폐병소의 근치절제술 후 일차 항결핵제로 구성된 처방으로 치료하였을 때의 성적을 알아보고자 하였다. 방 법 : 전향적 연구로 국립마산결핵병원에서 1998년 2월부터 2004년 12월 사이에 다제내성 폐결핵으로 수술전 HRCT에서 공동을 포함하는 국소적 병소인 것과 수술 중에 절제부위 이외에 잔존병소가 없다고 판단 된 환자 17명에게 수술 후 3HERZS/3HERS/6HER로 투약하고 그 임상적 경과를 살펴보았다. 결 과 : 대상환자들은 약제감수성검사에서 INH, RFP이외에 평균 4가지 항결핵제에 내성을 보였으며, 술 후 균음전은 평균 2일째 이루어졌다. 평균 39개월의 추구관찰 기간 동안 치료를 중단한 1명을 제외한 94%(15/16) 환자에서 치유되었으며 균음전에 실패한 1명과 치료종결하고 약 7년 후에 재발된 1명은 본원의 처방지침에 따라 이차 항결핵제로 처방을 변경 투약하여 모두 균음전에 성공하였다. 결 론 : 국소적 병변을 가진 다제내성결핵 환자에서 병소의 근치절제후 일차 항결핵제로 구성된 처방으로도 양호한 치료성적을 얻을 수 있었다. 하지만 이러한 경험을 일반화하기 위해서는 더 많은 경험과 병소별 결핵균 주의 특성에 관한 연구 등이 필요할 것으로 사료된다.

Keywords

References

  1. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993;329:784-91 https://doi.org/10.1056/NEJM199309093291108
  2. Report on the 7th tuberculosis prevalence survey in Korea. Ministry of Health and Welfare, Korean National Tuberculosis Association; 1996. p.1-180
  3. Dye C, Espinal MA, Watt CJ, Mbiaga C, Williams BG. Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis 2002;185:1197-202 https://doi.org/10.1086/339818
  4. Park SK, Choi IH, Kim CM, Kim CT, Song SD. Clinical study of pulmonary tuberculosis for admitted patients at National Masan Tuberculosis Hospital. Tuberc Respir Dis 1997;44:241-50 https://doi.org/10.4046/trd.1997.44.2.241
  5. Park SK, Lee IH, Kim BJ. Clinical observational study of pulmonary tuberculosis for admitted patients at a National Tuberculosis Hospital: comparison with the previous results in 1995. Tuberc Respir Dis 2005;58:392-8 https://doi.org/10.4046/trd.2005.58.4.392
  6. Canetti G, Grosset J. Percentage of isoniazid-resistant and streptomycin-resistant variants in wild strains of Mycobacterium tuberculosis on Loewenstein-Jensen medium. Ann Inst Pasteur 1961;101:28-46
  7. Iseman MD, Madsen L, Goble M, Pomerantz M. Surgical intervention of pulmonary disease caused by drug-resistant Mycobacterium tuberuclosis. Am Rev Respir Dis 1990;141:623-5 https://doi.org/10.1164/ajrccm/141.3.623
  8. van Leuven M, de Groot M, Shean KP, von Oppell UO, Willcox PA. Pulmonary resection as an adjunct in the treatment of multiple drug-resistant tuberculosis. Ann Thorac Surg 1997;63:1368-73 https://doi.org/10.1016/S0003-4975(97)80353-0
  9. Pomerantz M, Brown JM. Surgery in the treatment of multidrug-resistant tuberculosis. Clin Chest Med 1997;18:123-30 https://doi.org/10.1016/S0272-5231(05)70361-0
  10. Sung SW, Kang CH, Kim YT, Kim JH. Surgical management of multidrug resistant pulmonary tuberculosis. Korean J Thorac Cardiovasc Surg 1999;32:287-93
  11. Kwon ES, Ha HC, Hwang SH, Lee HY, Park SK, Song SD. Pulmonary resection in the treatment of multidrug-resistant tuberculosis. Tuberc Respir Dis 1998;45:1143-53 https://doi.org/10.4046/trd.1998.45.6.1143
  12. Park SK, Lee CM, Heu JP, Song SD. A retrospective study for the outcome of pulmonary resection in 49 patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2002;6:143-9
  13. Sim YS. Update in refractory pulmonary tuberculosis. J Korean Med Assoc 1998;39:1277-86
  14. Park SK, Choi IH, Song SD. Clinical course of cavitary lesions in pulmonary tuberculosis. Tuberc Respir Dis 1996;43:323-30 https://doi.org/10.4046/trd.1996.43.3.323
  15. Jun HJ, Hahn DK, Park SK, Song SD, Choi PC, Woo JS. Clinical evaluation of surgical resection of surgical resection on pulmonary tuberculosis: multiple drug resistant tuberculosis. Korean J Thorac Cardiovasc Surg 1997;30:786-92
  16. Pomerantz M, Brown J. The surgical management of tuberculosis. Semin Thorac Cardiovasc Surg 1995;7:108-11
  17. Sim SB, Kim OJ, Kim BS, Jang DC. Clinical evaluation of posititve sputum AFB cases following pulmonary resection of pulmonary tuberculosis. Korean J Thorac Cardiovasc Surg 1992;25:856-62
  18. van Rie A, Warren R, Richardson M, Victor TC, Gie RP, Enarson DA, et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999;341:1174-9 https://doi.org/10.1056/NEJM199910143411602
  19. Kim AJ, Kuh JH, Kim KS. Surgical treatment of pulmonary tuberculosis. Korean J Thorac Cardiovasc Surg 1996;29:397-402
  20. Pomerantz M. Madsen L, Goble M, Iseman MD. Surgical management of resistant mycobacterial tuberculosis and other mycobacterial pulmonary infections. Ann Thorac Surg 1991;52:1108-11 https://doi.org/10.1016/0003-4975(91)91289-8
  21. Kaplan G, Post FA, Moreira AL, Wainwright H, Kreiswirth BN, Tanverdi M, et al. Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun 2003;71:7099-108 https://doi.org/10.1128/IAI.71.12.7099-7108.2003
  22. Post FA, Willcox PA, Mathema B, Steyn LM, Shean K, Ramaswamy SV, et al. Genetic polymorphisms in Mycobacterium tuberculosis isolates from patients with chronic multidrug-resistant tuberculosis. J Infect Dis 2004;190:99-106 https://doi.org/10.1086/421501
  23. Song W, Woo HJ, Kim JS, Lee KM. In vitro activity of beta-lactams in combination with other antimicrobial agents against resistant strains of Pseudomonas aeruginosa. Int J Antimicrob Agents 2003;21:8-12 https://doi.org/10.1016/S0924-8579(02)00269-8
  24. Yoon J, Urban C, Terzian C, Mariano N, Rahal JJ. In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2004;48:753-7 https://doi.org/10.1128/AAC.48.3.753-757.2004
  25. Fish DN, Choi MK, Jung R. Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs. J Antimicrob Chemother 2002;50:1045-9 https://doi.org/10.1093/jac/dkf211
  26. Urban C, Segal-Maurer S, Rahal JJ. Considerations in control and treatment of nosocomial infections due to multidrug resistant Acinetobacter baumannii. Clin Infect Dis 2003;36:1268-74 https://doi.org/10.1086/374847